由于中风和血管器械销售的增长,Penumbra在2025年第四季度的收益估计超过了预期. Penumbra beat earnings estimates in Q4 2025, driven by growth in stroke and vascular device sales.

Penumbra(NYSE:PEN)报告,2025年第四季度收入为每股1.18美元,超过1.12美元的估计数,收入为3.854亿美元,比预计的3.6718亿美元有所增加。 Penumbra (NYSE:PEN) reported fourth-quarter 2025 earnings of $1.18 per share, exceeding the $1.12 estimate, with revenue of $385.4 million, up from $367.18 million projected. 该公司2025年全年净收入为1.777亿美元,收入14亿美元。 The company posted full-year 2025 net income of $177.7 million and $1.4 billion in revenue. 这标志着连续第三季度的EPS节拍,其驱动因素是中风和血管治疗医疗设备组合的增长。 This marks the third consecutive quarter of EPS beats, driven by growth in its medical device portfolio for stroke and vascular treatments. 库存关闭额为339.44美元,下降0.15美元,交易额低于平均交易额。 The stock closed at $339.44, down $0.15, with lower-than-average trading volume. 分析员持有好坏参半的前景,有一致的“稳住”评级和358美元平均价格目标。 Analysts maintain a mixed outlook, with a consensus "Hold" rating and a $358 average price target.